INNO-LIA® HIV I/II Score

The clearest answer in HIV confirmation

Line immunoassay for the confirmation and discrimination of antibodies to HIV-1, HIV-1 group O and HIV-2 in human serum and plasma.

    Contact sales for information
    CE marked (IVDR)
    INNO-LIA® HIV I/II Score

    Product number 80540

    20 Tests
    Please contact your local Fujirebio representative for the availability of this product in your country.

    Click here to navigate

    • Contact sales for information
    • Details
    • Conditions of sale
    • Citations
    • Documentation
    • Insights
    • Product inquiry
    • Related products

    • Details

       

       

       
      Features & Benefits

      • All major HIV strains detectable with one strip: HIV-1, HIV-2, and HIV-1 group O
      • Optimal specificity in screened-negative blood donors: 96.7% (290/300)
      • High sensitivity in BBI panels
      • Short and overnight procedures
      • Color-coded reagents
      • Ready-to-use reagents
      • Four control lines to monitor 1) non-specific reactivity, 2) sample addition,  3) and 4) color development steps
      • Fully automated strip processing possible using TENDIGO™, Auto-LIA™ 48, Auto-LiPA™ 48, AutoBlot 3000(H) or Roboblot®
      • Objective, automated reading and interpretation of the strips possible using LiRAS® for Infectious Diseases

       
      Background

      Antibodies to human immunodeficiency virus (HIV) have been detected in most patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC), and in many asymptomatic individuals belonging to high-risk groups. Enzyme-linked immunosorbent assays (ELISA) are widely used to screen human blood and plasma samples for the presence of these HIV antibodies.

      However, since false-positive reactions have frequently been observed with current ELISA tests, it is strongly recommended to confirm repeatedly reactive samples by use of other reliable techniques (such as the INNO-LIA HIV I/II Score). Recombinant proteins and synthetic peptides from HIV-1 and HIV-2, and a synthetic peptide from HIV-1 group O, are coated as discrete lines on a nylon strip with plastic backing.

      The INNO-LIA HIV I/II Score assay contains sequences derived from HIV-O sequences to allow the optimal detection of infections caused by this group of viruses. To allow the broad spectrum detection of all HIV infections, the INNO-LIA HIV I/II Score assay also contains separate lines for the differentiation of HIV-1 and HIV-2 infections.

      This is important, as HIV-2 is less virulent, resulting in a better prognosis for the patient.

    • Conditions of sale

      To read the end user conditions of sale for this product please visit our Resource center.

    • Citations

    • Insights

    • Product inquiry

      CAPTCHA

      The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

      For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

      If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

    Veuillez confirmer que vous êtes un professionnel de la santé

    Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

    Choose your country or region

    Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
    The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.